IL302873A - Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance Modulators - Google Patents
Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance ModulatorsInfo
- Publication number
- IL302873A IL302873A IL302873A IL30287323A IL302873A IL 302873 A IL302873 A IL 302873A IL 302873 A IL302873 A IL 302873A IL 30287323 A IL30287323 A IL 30287323A IL 302873 A IL302873 A IL 302873A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- therapeutic agent
- additional therapeutic
- independently selected
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115552P | 2020-11-18 | 2020-11-18 | |
| PCT/US2021/072475 WO2022109573A1 (en) | 2020-11-18 | 2021-11-17 | Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302873A true IL302873A (en) | 2023-07-01 |
Family
ID=79602287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302873A IL302873A (en) | 2020-11-18 | 2021-11-17 | Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance Modulators |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP4247817A1 (es) |
| JP (1) | JP2023549547A (es) |
| KR (1) | KR20230123522A (es) |
| CN (1) | CN116670140A (es) |
| AR (1) | AR124090A1 (es) |
| AU (1) | AU2021383176A1 (es) |
| CA (1) | CA3201793A1 (es) |
| CL (1) | CL2023001398A1 (es) |
| CO (1) | CO2023007896A2 (es) |
| CR (1) | CR20230260A (es) |
| DO (1) | DOP2023000099A (es) |
| EC (1) | ECSP23045439A (es) |
| GE (1) | GEAP202316271A (es) |
| IL (1) | IL302873A (es) |
| JO (1) | JOP20230105A1 (es) |
| MX (1) | MX2023005721A (es) |
| PE (1) | PE20231380A1 (es) |
| WO (1) | WO2022109573A1 (es) |
| ZA (1) | ZA202305296B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP2025506382A (ja) * | 2022-02-03 | 2025-03-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
| JP2025505643A (ja) * | 2022-02-08 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子の調節因子 |
| WO2023224931A1 (en) * | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| JP2025517323A (ja) | 2022-05-16 | 2025-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒモジュレーターとしての大環状化合物の固体形態及びその調製 |
| WO2024054851A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
| CN119998297A (zh) | 2022-09-15 | 2025-05-13 | 爱杜西亚药品有限公司 | (3S,7S,10R,13R)-13-苄基-20-氟-7-异丁基-N-(2-(3-甲氧基-1,2,4-噁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四氧代-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氢-[1]氧杂[4,7,10,14]四氮杂环十七烷并[16,17-f]喹啉-3-甲酰胺的晶型 |
| WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
| CA3267788A1 (en) * | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103946221B (zh) * | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| CN109803962B (zh) * | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| MD3551622T2 (ro) * | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JP7214743B2 (ja) * | 2018-02-15 | 2023-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 |
| CN109134431B (zh) * | 2018-10-10 | 2021-06-04 | 成都理工大学 | 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物 |
| UY38630A (es) * | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
-
2021
- 2021-11-17 CA CA3201793A patent/CA3201793A1/en active Pending
- 2021-11-17 CN CN202180090910.1A patent/CN116670140A/zh active Pending
- 2021-11-17 PE PE2023001653A patent/PE20231380A1/es unknown
- 2021-11-17 MX MX2023005721A patent/MX2023005721A/es unknown
- 2021-11-17 AU AU2021383176A patent/AU2021383176A1/en active Pending
- 2021-11-17 GE GEAP202316271A patent/GEAP202316271A/en unknown
- 2021-11-17 WO PCT/US2021/072475 patent/WO2022109573A1/en not_active Ceased
- 2021-11-17 CR CR20230260A patent/CR20230260A/es unknown
- 2021-11-17 EP EP21843853.9A patent/EP4247817A1/en active Pending
- 2021-11-17 IL IL302873A patent/IL302873A/en unknown
- 2021-11-17 KR KR1020237020002A patent/KR20230123522A/ko active Pending
- 2021-11-17 JP JP2023529022A patent/JP2023549547A/ja active Pending
- 2021-11-18 AR ARP210103184A patent/AR124090A1/es unknown
-
2023
- 2023-05-11 JO JOJO/P/2023/0105A patent/JOP20230105A1/ar unknown
- 2023-05-15 ZA ZA2023/05296A patent/ZA202305296B/en unknown
- 2023-05-16 CL CL2023001398A patent/CL2023001398A1/es unknown
- 2023-05-17 DO DO2023000099A patent/DOP2023000099A/es unknown
- 2023-06-16 EC ECSENADI202345439A patent/ECSP23045439A/es unknown
- 2023-06-16 CO CONC2023/0007896A patent/CO2023007896A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023001398A1 (es) | 2023-11-24 |
| EP4247817A1 (en) | 2023-09-27 |
| CO2023007896A2 (es) | 2023-09-18 |
| ECSP23045439A (es) | 2023-08-31 |
| AR124090A1 (es) | 2023-02-15 |
| CA3201793A1 (en) | 2022-05-27 |
| JP2023549547A (ja) | 2023-11-27 |
| MX2023005721A (es) | 2023-07-25 |
| DOP2023000099A (es) | 2023-08-15 |
| ZA202305296B (en) | 2025-09-25 |
| PE20231380A1 (es) | 2023-09-07 |
| JOP20230105A1 (ar) | 2023-05-11 |
| KR20230123522A (ko) | 2023-08-23 |
| GEAP202316271A (en) | 2023-10-25 |
| CN116670140A (zh) | 2023-08-29 |
| AU2021383176A1 (en) | 2023-06-22 |
| WO2022109573A1 (en) | 2022-05-27 |
| CR20230260A (es) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL302873A (en) | Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance Modulators | |
| JP7550870B2 (ja) | Ｙａｐ／ｔａｚ－ｔｅａｄタンパク質－タンパク質相互作用阻害剤としてのビアリール誘導体 | |
| RU2435771C2 (ru) | Производные спироиндолинона | |
| TWI885983B (zh) | 三環性螺化合物之用途 | |
| AU2018332887B2 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| AU2008228186C1 (en) | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | |
| RU2701156C2 (ru) | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах | |
| IL300298B1 (en) | Apol1 inhibitors and methods of use are the same | |
| US11319303B2 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
| JP2014506599A5 (es) | ||
| JP2015500275A5 (es) | ||
| SI3022192T1 (en) | Piperidinyl indole derivatives and their use as inhibitors of complementary factor B | |
| JPWO2022032068A5 (es) | ||
| JP2010536887A5 (es) | ||
| CN111484491B (zh) | 取代吡啶并环化合物、其制备方法和用途 | |
| ZA200100913B (en) | New compounds. | |
| JP2023514725A (ja) | 化合物および使用方法 | |
| AU2013328609B2 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
| AU2018228114B2 (en) | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | |
| JP2013536233A5 (es) | ||
| RS51389B (sr) | Jedinjenja benzimidazola | |
| JP2015500277A (ja) | アンドロゲン受容体拮抗薬としての環状尿素誘導体 | |
| US12503474B2 (en) | Substituted pyrrolo[1,2-b]pyridazines as anthelmintics | |
| EP4007578A1 (en) | Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| IL291396B1 (en) | MLL1 inhibitors and anticancer drugs |